Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Mathieu, Chevallier"'
Publikováno v:
healthbook TIMES. Oncology Hematology (2024)
Metastatic breast cancer continues to present significant therapeutic challenges, necessitating ongoing exploration of innovative treatments. The use of antibody-drug conjugates (ADCs) represents an effective treatment strategy that combines the targ
Externí odkaz:
https://doaj.org/article/b737c57770cb4f7cb0e058040b5d8f97
Autor:
Xavier Baer, Mathieu Chevallier, Juliana Rey Cobo, Jérôme Plojoux, Claudio De Vito, Alfredo Addeo
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 549-555 (2024)
Introduction: Lung cancer is the second most common cancer; however, synchronous lung cancer is rare and challenging to treat. Case Presentation: We report the case of an 80-year-old female patient who presented with two lung lesions with primary tum
Externí odkaz:
https://doaj.org/article/1f65cc6ec3514b10a9afd9dd782270f0
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 17 (2023)
Over the course of the last decade, immunotherapy has revolutionised the management of a great number of cancer types. The treatment of pleural mesothelioma, a rare and highly aggressive cancer, is also being transformed by immunotherapy. The recent
Externí odkaz:
https://doaj.org/article/7310d37f691b42c6b60efee744c4f299
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 1, Pp 279-283 (2021)
Bone is a frequent site of metastases in advanced cancers including lung, breast, prostate, kidney, or myeloma. Lesions are commonly located on the spine. Neoplastic invasion of the vertebral body can result in painful vertebral fractures, leading to
Externí odkaz:
https://doaj.org/article/97525a8ec464487eb7983708845549c6
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
EGFR mutations represent the most common currently targetable oncogenic driver in non-small cell lung cancer. There has been tremendous progress in targeting this alteration over the course of the last decade, and third generation tyrosine kinase inh
Externí odkaz:
https://doaj.org/article/e95538fb03f54396b52b2d6c7006b2e4
Publikováno v:
Cancer Genomics & Proteomics, Vol. 17, No 5 (2020) pp. 597-603
Cancer Genomics Proteomics
Cancer Genomics Proteomics
Background/Aim: Non-small cell lung cancer (NSCLC) patients with activating somatic mutations in the epidermal growth factor receptor (EGFR) have better outcomes with tyrosine kinase inhibitors (TKIs) than with chemotherapy. However, even with the mo
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol. 11 (2021) P. 644472
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol. 11 (2021) P. 644472
EGFR mutations represent the most common currently targetable oncogenic driver in non-small cell lung cancer. There has been tremendous progress in targeting this alteration over the course of the last decade, and third generation tyrosine kinase inh
Publikováno v:
Revue Médicale Suisse. 15:1188-1192
Publikováno v:
Clinics of Oncology.
Publikováno v:
Revue medicale suisse. 15(654)
With the emergence of new antitumoral agents and their benefit on patient survival, general practitioners are increasingly facing the challenges of managing patients with oncologic conditions. As a result, they have a key role in the follow-up of the